Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis

Radiat Med. 1992 Sep-Oct;10(5):189-95.

Abstract

We examined 35 untreated patients with unresectable hepatocellular carcinoma who exhibited positivity for both plasma PIVKA-II and serum AFP, and studied the weekly course of these markers from the pre-TAE or -HAI period to the third week of treatment. We correlated changes in these markers with the tumor necrosis rate and the time course on X-ray CT images. One week after TAE, the tumor necrosis rate and the time course of PIVKA-II showed a significant correlation (r = 0.7), while the correlation was between the time course of AFP and the tumor necrosis rate was insignificant (r = 0.2). At two and three weeks after TAE, both the time course of AFP and PIVKA-II showed significant correlations with the tumor necrosis rate. In 16 patients with tumor necrosis rates of not less than 90%, the mean of the actual half-life (AHL) of PIVKA-II was 3.2 days, the shortest was 1.83 days, and 75% of all AHLs clustered from two days to four days, while the mean and shortest AHLs of AFP were six days and 2.98 days, respectively, exhibiting a broader distribution. On the other hand, in three out of the nine cases of hepatocellular carcinoma complicated with portal tumor thrombi, PIVKA-II increased after HAI in spite of a reduction in tumor size. It was suggested that the PIVKA-II level requires careful interpretation in cases of portal vein obstruction after intensive hepatic arterial infusion of anticancer agents.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Biomarkers*
  • Biomarkers, Tumor
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / therapy*
  • Cisplatin / administration & dosage
  • Doxorubicin / administration & dosage
  • Embolization, Therapeutic*
  • Female
  • Hepatic Artery*
  • Humans
  • Infusions, Intra-Arterial*
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / therapy*
  • Male
  • Middle Aged
  • Mitomycin / administration & dosage
  • Protein Precursors / analysis*
  • Prothrombin / analysis*
  • Tomography, X-Ray Computed
  • alpha-Fetoproteins / analysis*

Substances

  • Biomarkers
  • Biomarkers, Tumor
  • Protein Precursors
  • alpha-Fetoproteins
  • Mitomycin
  • acarboxyprothrombin
  • Doxorubicin
  • Prothrombin
  • Cisplatin